| GRI index - Human Rights | |||||
| Indicator | Level of fulfilment | Where to find the indicator | Corresponding principle in Global Compact | Com- ment | |
| HR1 Percentage and total number of significant investment agreements that include human rights clauses or that have undergone human rights screening. | - | Web: Human rights | 1, 2 | ||
| HR2 Percentage of significant suppliers and contractors that have undergone screening on human rights and actions taken. | + | Web: Human rights | 1 - 6 | ||
| HR3 Total hours of employee training on policies and procedures concerning aspects of human rights that are relevant to operations, including the percentage of employees trained. | - | Web: Human rights | 1 - 6 | ||
| HR4 Total number of incidents of discrimination and actions taken. | - | Web: Human rights | 6 | ||
| HR5 Operations identified in which the right to exercise freedom of association and collective bargaining may be at significant risk, and actions taken to support these rights. | + | Web: Human rights | 3 | ||
| HR6 Operations identified as having significant risk for incidents of child labor, and measures taken to contribute to the elimination of child labor. | - | Web: Human rights | 5 | ||
| HR7 Operations identified as having significant risk for incidents of forced or compulsory labor, and measures taken to contribute to the elimination of forced or compulsory labor. | - | Web: Human rights | 4 | ||
| HR8 Percentage of security personnel trained in the organization’s policies or procedures concerning aspects of human rights that are relevant to operations. | + | Web: Human rights | 1, 2 | ||
| HR9 Total number of incidents of violations involving rights of indigenous people and actions taken. | - | Web: Human rights | 1, 2 | ||
Exclusively for Health Care Professionals. Stay up to date on Novo Nordisk diabetes products: Victoza®, Levemir®, NovoMix®, NovoRapid® and Devices, and read about current diabetes themes, proven therapeutic options, and knowledge resources and tools for you and your patients.
Overview
NovoSeven®
270 µg/kg dose
Room temperature stable
8 mg vial
Management
Blood coagulation
Key papers
Treatment guidelines
Services & links
WFH patients'
leaflet
Patient story
Congenital haemophilia
Acquired haemophilia
Factor VII deficiency
Glanzmann's
thrombasthenia
Overview
GHD (Growth hormone deficiency)
GHDA (Growth hormone deficiency) in adults
SGA (Small for gestational age)
Turner syndrome
Noonan syndrome
Skeletal dysplasia
Chronic renal disease
Norditropin®
Norditropin® FlexPro®
Norditropin NordiFlex®
NordiFlex PenMate®
NordiPen® with Norditropin® SimpleXx®
NordiPenMate®
Norditropin® NordiLet®
NovoFine®
NordiNet® (outcomes registry)
NordiScience® (HCP support)
NordiCare® (Patient support)
Our partnership with Save the Children
Testimonials
Overview
Introduction
Activelle®
Eviana®
Novofem®
Estrofem®
Vagifem®
Convenience & compliance
Our history in HRT
Introduction
Symptoms & complaints
Duration of treatment
Oestrogen
Progestogen
Continuous combined HRT
Sequential combined HRT
Low-dose HRT
According to applicable law, only Health Care Professionals are allowed to access the product information in this section.
Information for patients and relatives
Do you have a recent master degree, and do you want a successful career in one of the world's leading pharmaceutical companies? If yes, then the Novo Nordisk Graduate Programme is what you are looking for.
Novo Nordisk is a global healthcare company with 88 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy.
Headquartered in Denmark, Novo Nordisk employs approximately 31,400 employees in 74 countries, and markets its products in 179 countries.
Novo Nordisks B shares are listed on NASDAQ OMX Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO).








